Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy.

International Journal of Hematology
Satoshi NishiwakiTomoki Naoe

Abstract

Hemophagocytic syndrome (HPS) induced by uncontrolled macrophage activation and subsequent graft failure is a frequent and prominent complication after allogeneic stem cell transplantation (allo-SCT), a cause of severe morbidity and death, and a therapeutic challenge. Liposome-incorporated dexamethasone, dexamethasone palmitate (DP), shows greater efficacy against macrophages as compared to dexamethasone sodium phosphate (DSP). Based on our findings that DP achieves significantly larger decrease than DSP on the viability of primary human macrophages compared in vitro, we tested the effects of DP in patients with HPS. A decrease in number of macrophages in the bone marrow and prevention of engraftment failure were observed in all patients without any severe complications. In conclusion, these data provide a rationale for testing DP as a first-line treatment for patients with HPS after allo-SCT.

References

Mar 1, 1976·Annals of Internal Medicine·A S FauciJ E Balow
Jan 1, 1991·Biotherapy·C C Pak, I J Fidler
Nov 9, 2004·Trends in Immunology·Alberto MantovaniMassimo Locati
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Fernando O MartinezAlberto Mantovani
Dec 17, 2008·International Journal of Antimicrobial Agents·Isabel Ruiz Camps
Jan 14, 2009·Bone Marrow Transplantation·Y InamotoUNKNOWN Nagoya Blood and Marrow Transplantation Group
Aug 28, 2009·British Journal of Haematology·Shinsuke TakagiShuichi Taniguchi
Feb 15, 2011·The Journal of Clinical Investigation·Anca SindrilaruKarin Scharffetter-Kochanek

❮ Previous
Next ❯

Citations

Apr 24, 2014·Modern Rheumatology·Yasuo NakagishiAkihiro Yachie
Dec 2, 2015·International Journal of Hematology·Sarita Rani JaiswalSuparno Chakrabarti
Jun 21, 2016·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Hiroyuki Wakiguchi, Shouichi Ohga
Nov 7, 2016·Journal of Clinical Immunology·Shintaro OnoHirokazu Kanegane
Mar 9, 2021·International Journal of Hematology·Masayuki NagasawaTomohiro Morio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.